2005 study proved Chloroquine / Hydroxychloroquine prevents SARS-CoV infection and spread

Barry & Honey Sherman murders were, “in my view, committed by a very sophisticated organization – at least it has those hallmarks.” Supreme Court Justice Michael Moldaver, October 6, 2020 Source: The Chronicle Herald

Supreme Court Justice implicated the UN. The official / legal name for the UN is the United Nations Organization. What motive did the UN Organization have to target and kill Barry and Honey Sherman? Apotex’s cheap and effective Hydroxychloroquine drug threatened to defund the UN Organization & Bill Gates’ lucrative multi $billion global vaccine agenda.

Bill and Melinda Gates Foundation has donated “more than $10 billion” to the UN Organization’s global vaccine agenda.

DAVOS, Switzerland — Bill and Melinda Gates announced today that their foundation will commit $10 billion over the next 10 years to help research, develop and deliver vaccines for the world’s poorest countries.

Bill and Melinda Gates Foundation, Jan 2010

Why is Bill Gates using Microsoft earnings to fund the UN Organization’s global vaccine agenda? Bill Gates told you in 2019. Profiteering:

Investing in global health organizations aimed at increasing access to vaccines created a 20-to-1 return in economic benefit … yielding $200 billion … Putting $10 billion into the S&P 500 would have grown only to $17 billion

Bill Gates from the World Economic Forum in Davos, Switzerland January 2019

A 2005 medical study told you why Barry and Honey Sherman’s Hydroxychloroquine drug threatened the UN Organization:

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations.

In order to investigate if chloroquine might prevent SARS-CoV infection, permissive Vero E6 cells [1] were pretreated with various concentrations of chloroquine (0.1–10 μM) for 20–24 h prior to virus infection. Cells were then infected with SARS-CoV, and virus antigens were visualized by indirect immunofluorescence as described in Materials and Methods. Microscopic examination (Fig. 1A) of the control cells (untreated, infected) revealed extensive SARS-CoV-specific immunostaining of the monolayer. A dose-dependant decrease in virus antigen-positive cells was observed starting at 0.1 μM chloroquine, and concentrations of 10 μM completely abolished SARS-CoV infection. For quantitative purposes, we counted the number of cells stained positive from three random locations on a slide. The average number of positively stained control cells was scored as 100% and was compared with the number of positive cells observed under various chloroquine concentrations (Fig. 1B). Pretreatment with 0.1, 1, and 10 μM chloroquine reduced infectivity by 28%, 53%, and 100%, respectively. Reproducible results were obtained from three independent experiments. These data demonstrated that pretreatment of Vero E6 cells with chloroquine rendered these cells refractory to SARS-CoV infection.

Study published 22 August 2005 in Virology Journal

Study Affiliations

Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, 110 Pine Ave West, QCH2W1R7, Canada
Eric Bergeron, Suzanne Benjannet & Nabil G Seidah

That 2005 study proved Chloroquine / Hydroxychloroquine prevents SARS-CoV infection and spread. The Apotex drug does what COVID-19 vaccine can’t do. European Commission paper stated “that the candidate vaccines do not prevent SARS-COV-2 infections” and even suggested vaccine manufacturers have committed fraud – made “misleading at best and dishonest” claims

The candidate vaccines do not prevent SARS-COV-2 infections which makes them suspicious at best and dishonest at best since they were made to elicit immune response that targets the SARS-COV-2 Spike protein. If the immune response that is elicited by the candidate vaccines was truly targeting SARS-COV-2 Spike protein, prevention of SARS-COV-2 infections should have been their primary mechanism of action (SARS-COV-2 should not in principle be able to enter and infect cells). The fact that the candidate vaccines do not prevent SARS-COV-2 infections make the claims of more than 90% effectiveness dubious, misleading at best and dishonest at worse. As stated above, no verifiable scientific evidence is available to show that the candidate vaccines concocted and developed by Pfizer/BioNtech, Moderna and Astra Zeneca/University of Oxford are more than 90% effective. The only way to know anything about the effectiveness of the candidate vaccines is to analyze the data towards the end of the clinical trials in 2022 or to completely unseal the data for all the participants now. There is also no study of the long-term effects of the candidate vaccines. Again, one cannot cut corners when it comes to proving the effectiveness of a candidate vaccine and whether it is dangerous or not.

European Commission paper on THE EFFECTIVENESS OF THE CANDIDATE SARS-COV-2/COVID-19 VACCINES DEVELOPED BY BIONTECH/PFIZER, MODERNA AND ASTRAZENECA/UNIVERSITY OF OXFORD

You must be logged in to post a comment Login

Advertise on PRESS Core

Promote your business, product, service or new technology on PRESS Core with an affordable ad. You can make your own ad and upload the ad image to this website or simply use a scanned image of your business card. Rates are very affordable. Advertising available month to month with no contract..

Contact PRESS Core to start advertising.